# Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI

Study · id `cardio:ct-nct04499859` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04499859](<https://clinicaltrials.gov/study/NCT04499859>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04499859

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3548 participants.

## Technical summary

Registry record NCT04499859. Randomized; no masking; primary purpose treatment. Start 2020-10-01 (actual); primary completion 2026-08-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3548 participants (planned count; ClinicalTrials.gov record NCT04499859, source copy `cardio:ctgov-nct04499859-2025-07-30`, retrieved 2026-10-26)
- Started: 2020-10-01 (actual) (ClinicalTrials.gov record NCT04499859, source copy `cardio:ctgov-nct04499859-2025-07-30`, retrieved 2026-10-26)
- Primary completion: 2026-08-30 (anticipated) (ClinicalTrials.gov record NCT04499859, source copy `cardio:ctgov-nct04499859-2025-07-30`, retrieved 2026-10-26)
- Completion: 2027-08-30 (anticipated) (ClinicalTrials.gov record NCT04499859, source copy `cardio:ctgov-nct04499859-2025-07-30`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04499859, source copy `cardio:ctgov-nct04499859-2025-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04499859-2025-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
- Acronym: ROSUZET-AMI
- Condition: Myocardial Infarction
- Condition: Statin Adverse Reaction
- Condition: HMG-CoA Reductase Inhibitor Toxicity
- Intervention (Drug): Ezetimibe 10mg + Rosuvastatin 5mg
- Intervention (Drug): Rosuvastatin 20mg
- Lead sponsor: Kiyuk Chang, MD,PhD
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)

## Provenance

Content hash: 5dd29f3c4a54ed32c30b2b0dc8c62477c7957c6cc6568ee04e24374b93c4b389
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
